Questionnaire February 2010

Similar documents
Standing Committee on TRIPS Standing Committee on IP and Genetic Resources / Traditional Knowledge

Multilateral negotiations on IP - Traditional Knowledge and Genetic resources

THE RELATIONSHIP BETWEEN THE TRIPS AGREEMENT AND THE CONVENTION ON BIOLOGICAL DIVERSITY AND THE PROTECTION OF TRADITIONAL KNOWLEDGE

Subregional Seminar on the Legal Protection of Biotechnology and Genetic Resources Banska Bystrica, May 2 and 3, Access and Benefit Sharing

CBD Request to WIPO on the Interrelation of Access to Genetic Resources and Disclosure Requirements

Genetic Resources and Intellectual Property: Recent developments under the Convention on Biological Diversity

Intellectual Property and Genetic Resources: Relationship with Relevant International Instruments

GENEVA INTERGOVERNMENTAL COMMITTEE ON INTELLECTUAL PROPERTY AND GENETIC RESOURCES, TRADITIONAL KNOWLEDGE AND FOLKLORE

Different Options for ABS in Relation to Marine Genetic Resources in ABNJ

ADDRESSING THE DISCLOSURE REQUIREMENT AT THE INTERNATIONAL LEVEL - THE ROLE OF THE TRIPS AGREEMENT

NAGOYA PROTOCOL ON ACCESS TO GR AND BENEFIT SHARING (ABS): CHALLENGES AND OPPORTUNITIES FOR MICROBIOLOGY DR. ALEJANDRO LAGO CANDEIRA

THE ASEAN FRAMEWORK AGREEMENT ON ACCESS TO BIOLOGICAL AND GENETIC RESOURCES

Access and Benefit Sharing (Agenda item III.3)

BIOPIRACY: FACT OR FICTION? INTERNATIONAL TREATY NEGOTIATIONS COULD AFFECT YOUR IP RIGHTS AND YOUR BOTTOM LINE

Finland Russia Ukraine CONTENTS

Identifying and Managing Joint Inventions

Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities

Te Hunga Roia Maori o Aotearoa (Maori Law Society Inc.)

Patents AIA Move to First-to-File

Patents. What is a patent? What is the United States Patent and Trademark Office (USPTO)? What types of patents are available in the United States?

BioTrade and the Implementation of the Nagoya Protocol

The TRIPS Agreement and Patentability Criteria

ISSUES LINKED TO CONVENTION ON BIOLOGICAL DIVERSITY IN THE WTO

A POLICY in REGARDS to INTELLECTUAL PROPERTY. OCTOBER UNIVERSITY for MODERN SCIENCES and ARTS (MSA)

Question Q 159. The need and possible means of implementing the Convention on Biodiversity into Patent Laws

WORLD TRADE ORGANIZATION

Questionnaire May Q178 Scope of Patent Protection. Answer of the French Group

AN OVERVIEW OF THE UNITED STATES PATENT SYSTEM

AN OVERVIEW OF THE UNITED STATES PATENT SYSTEM

Item 7.4 of the Provisional Agenda SEVENTH SESSION OF THE GOVERNING BODY. Kigali, Rwanda, 30 October - 3 November 2017

Geneva, November 10-14, Topic 2: Patents

The Nagoya Protocol. Overview of the Nagoya Protocol

THE UNIVERSITY OF AUCKLAND INTELLECTUAL PROPERTY CREATED BY STAFF AND STUDENTS POLICY Organisation & Governance

WTO-ESCAP-IIUM Regional Workshop on IP and Public Health and Environment Policy for Asian and Pacific Region

INTRODUCTION TO THE ARIPO PATENT SYSTEM AND PROCEDURES

GUITAR PRO SOFTWARE END-USER LICENSE AGREEMENT (EULA)

Presented at GIZ/SAWTEE Training on IPR 1-2 March 2012, Laltipur. Ratnakar Adhikari South Asia Watch on Trade, Economics and Environment

Loyola University Maryland Provisional Policies and Procedures for Intellectual Property, Copyrights, and Patents

WIPO WORLD ORGANIZATION

DERIVATIVES UNDER THE EU ABS REGULATION: THE CONTINUITY CONCEPT

Note by the Executive Secretary

Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore

Topic 3 - Chapter II.B Primary consideration before drafting a patent application. Emmanuel E. Jelsch European Patent Attorney

Standing Committee on the Law of Patents

Intellectual Property and Sustainable Development

International IP. Prof. Eric E. Johnson. General Principles

The 45 Adopted Recommendations under the WIPO Development Agenda

MPEP Breakdown Course

Accepting Equity When Licensing University Technology

The relationship between the IR, the WTO, UPOV Convention and WIPO. Jorge Cabrera Medaglia

PATENT PROTECTION FOR PHARMACEUTICAL PRODUCTS IN CANADA CHRONOLOGY OF SIGNIFICANT EVENTS

Accepting Equity When Licensing University Technology

Establishing a Development Agenda for the World Intellectual Property Organization

Søren Flensted Lassen, Novozymes A/S 07 June 2016

INTELLECTUAL PROPERTY AND ENVIRONMENT: THE RELATIONSHIP BETWEEN THE CONVENTION ON BIOLOGICAL DIVERSITY AND THE TRIPS AGREEMENT DRAFT WORKING PAPER

Innovation Office. Intellectual Property at the Nelson Mandela University: A Brief Introduction. Creating value for tomorrow

Intellectual Property Rights and Marine Genetic Resources of the Areas beyond National Jurisdiction

Facilitating Technology Transfer and Management of IP Assets:

Introduction to Intellectual Property

WORLD TRADE ORGANIZATION

INTELLECTUAL PROPERTY OVERVIEW. Patrícia Lima

Patent Office. Patent Administration And Certificate section And Controlling group. Patent. Licensing and Opposition. Group. PCT receiving office

Intellectual Property Corporation of Malaysia

Functionality of the Nagoya ABS Protocol with a view to AnGR and a side-look to Anti- Conterfeiting Trade Agreement (ACTA)

What is Intellectual Property?

Enforcement Regulations of the Pharmaceutical Affairs Law

Access and Benefit Sharing: Case studies and International experience

UW REGULATION Patents and Copyrights

Study Guidelines Study Question (Designs) Requirements for protection of designs

Technology Transfer and Intellectual Property Best Practices

Intellectual Property

Invention SUBMISSION BROCHURE PLEASE READ THE FOLLOWING BEFORE SUBMITTING YOUR INVENTION

FICPI views on a novelty grace period in a global patent system

Client s Statement of Rights & Responsibilities*

WIPO s work on disclosure and protection of TK & GR Introduction in the Draft Provisions on TK and Revised List of Options on GR

5/30/2018. Prof. Steven S. Saliterman Department of Biomedical Engineering, University of Minnesota

National Intellectual Property Office in Sri Lanka (NIPO)

Convention on Biological Diversity: ABS. The Nagoya Protocol on Access and Benefit-sharing

WIPO Development Agenda

EL PASO COMMUNITY COLLEGE PROCEDURE

GENEVA INTERGOVERNMENTAL COMMITTEE ON INTELLECTUAL PROPERTY AND GENETIC RESOURCES, TRADITIONAL KNOWLEDGE AND FOLKLORE

Intellectual Property Law Alert

Intellectual Property Overview

Intellectual Property and Public Health - International Framework and Recent Developments in WIPO: SCP and CDIP

UCF Patents, Trademarks and Trade Secrets. (1) General. (a) This regulation is applicable to all University Personnel (as defined in section

RESOLUTION MEPC.290(71) (adopted on 7 July 2017) THE EXPERIENCE-BUILDING PHASE ASSOCIATED WITH THE BWM CONVENTION

TRAINING SEMINAR PHARMACEUTICALS AND INTELLECTUAL PROPERTY ACCESS TO MEDICINE: Exploitation of pharmaceutical patents: compulsory licences SESSION 4

GENEVA INTERGOVERNMENTAL COMMITTEE ON INTELLECTUAL PROPERTY AND GENETIC RESOURCES, TRADITIONAL KNOWLEDGE AND FOLKLORE

Fall National SBIR/STTR Conference

CBD/ Access and Benefit Sharing

Standing Committee on the Law of Patents

UNIVERSITY OF HAWAI I SYSTEM TESTIMONY

Topic 3: Patent Family Concepts and Sources for Family Information

Patent Due Diligence

LEGISLATIVE OPTIONS FOR TK AND

June 2014 For any information or queries relating to fundraising for headspace, please contact:

Prof. Steven S. Saliterman. Department of Biomedical Engineering, University of Minnesota

Policy Contents. Policy Information. Purpose and Summary. Scope. Published on Policies and Procedures (

F98-3 Intellectual/Creative Property

The UK Government Response to The Report of the Commission on Intellectual Property Rights "Integrating Intellectual Property Rights and Development

Transcription:

National Group: US Group Date: April 7, 2010 Questionnaire February 2010 Special Committees Q 94 WTO/TRIPS and Q166 Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore on the Requirement of indicating the source and/or country of origin of genetic resources and traditional knowledge in patent applications Introduction The United States has not become a party to the Convention on Biological Diversity. No pending legislation exists that would alter that status. The answers of the US group are not substantively different from the answers submitted in July 2006. Questions 1) Is there a legal requirement in your country that the source and/or country of origin of biological/genetic resources and traditional knowledge must be indicated in patent applications for inventions based on such biological/genetic resources or traditional knowledge? No. In the United States, there is no requirement to disclose the source or origin of genetic resources or associated traditional knowledge (GR/TK), whether in relation to the access and benefit sharing goals of the Convention on Biological Diversity (CBD), or otherwise. 1

To the extent that there is any requirement to disclose information regarding a genetic resource, it arises only as a consequence of application of the generally-defined requirements of patentability, e.g., novelty, non-obviousness, written description, and enablement. For example, information regarding a genetic resource may be necessary to meet the requirement for adequate disclosure under 35 U.S.C. 112, first paragraph if access to samples of the genetic resource is necessary to practice the claimed invention without undue experimentation, to demonstrate possession of the claimed invention, or to disclose the best mode known of practicing the invention at the time the application was filed. However, even in this case, there is no requirement to disclose the country of origin. There is only a requirement to provide access to the resource. If the claimed invention does not require any information related to the genetic resource (including a genetic resource that may have been used somehow in the course of developing the invention) in order to meet the disclosure requirements of 112, no additional disclosure is needed. Thus, whether there is a need to disclose information regarding a genetic resource will depend on the particular facts and circumstances of each application. An applicant may provide an adequate description of a genetic resource by a number of means. One would be to describe the physical characteristics of genetic resource by reference to objective, physical properties of the resource (e.g., structure, characteristics, etc). A second would be to provide a deposit of the genetic resource in a public depository, or refer to a prior deposit of the material. Finally, one could identify a location from which samples of the biological resource may be reliably obtained. Thus, to the extent that any obligation exists under U.S. patent law standards to identify a location from which samples of the biological material can be obtained, that obligation can be satisfied by providing a description of any location from which samples of the genetic resource can be obtained. In most instances where access to samples of a disclosed biological material is necessary, that obligation can be most efficiently discharged by providing a deposit of the material in a recognized depository institution, such as the American Type Culture Collection (ATCC). The U.S. patent law does not require a disclosure of the genetic or evolutionary origin of a genetic resource in any circumstance, as such information is not necessary to identify where one of skill could go to obtain a sample of the genetic resource. In other words, to 2

the extent that there is any disclosure obligation under the general U.S. patent law with regard to a genetic resource in a particular application, that obligation can be met by simply identifying any location from which a sample of the material can be obtained. If yes, please quote the corresponding text from the law or regulations and reply to the following questions, if applicable: No. There is no independent requirement for disclosure of source/origin of genetic resources or traditional knowledge. As such, there is no context in the U.S. system for this question. a) Are these regulations found in patent law, general IP laws or in legislation implementing the Convention on Biological Diversity? b) What "triggers" the disclosure requirement, i.e. how close must the relationship of the invention to the biological/genetic resource be to require disclosure? c) Is it clear what the concept of source or country of origin or "country providing the resource", and based on genetic resource/traditional knowledge or "derived from biological resource and associated traditional knowledge means and what information must be included in the patent application? No. We are not aware of a consistent or coherent definition of source, country of origin, or based on genetic resource/traditional knowledge. None of these terms is explicitly defined in the Convention on Biological Diversity (CBD), especially with regard to informing patent applicants as to the type of information that must be supplied, when or how extensive such information must be set forth in a patent application. As noted above, these concepts of source/origin are not requirements of the U.S. law, so there are no corresponding definitions of the terms. Under 35 U.S.C. 112, as explained above, an invention must be sufficiently described and enabled in the patent application. Section 112, however, is not concerned with or defined in reference to concepts of source or origin. These terms simply are not used in the U.S. patent law. 3

d) Is the disclosure requirement limited to biological/genetic resources or traditional knowledge of your country only or is it applicable also to biological/genetic resources or traditional knowledge obtained or obtainable from other countries and geographical areas? e) Are there ways to complement, correct or amend the corresponding text in the patent application after filing? f) Is disclosure of prior informed consent and/or agreements on fair and equitable benefit-sharing required? No. Disclosure of the existence of prior informed consent and/or agreements regarding benefit sharing are entirely irrelevant to the question of compliance with the disclosure requirements of 112, or other patentability criteria in the US system. g) Are human genetic resources treated differently or the same way as animal or plant genetic resources falling under the CBD? As indicated above, disclosure concepts are not relevant to, nor are they found in, U.S. standards relating to adequacy of disclosures or other substantive patentability criteria. h) Is traditional knowledge properly defined, and is the source of traditional knowledge to be indicated only if it is connected to genetic/biological resources (e.g. falling under the CBD) or in general? As noted above, there are no requirements in the U.S. patent system pertaining to genetic resources or traditional knowledge. Accordingly, there is no definition in the U.S. patent law concerning traditional knowledge. Information that may embody traditional knowledge, if publicly known in the US or published anywhere in the world prior to the effective filing date of the patent application, would be part of the prior art. 4

i) Are sanctions foreseen for non-compliance (e.g. patent invalidation, revocation or lack of enforceability, patent transfer to the owner of the resource, fines, criminal sanctions etc.)? j) Does the law/regulation indicate that access to a genetic/biological resource would not mandate a disclosure in the patent application, if such access had occurred prior to a particular date, e.g. prior to the date of entry into force of the CBD? 2) Please indicate your experience with the application of the legal requirement as listed under 1) when filing and prosecuting patent applications in your country. 3) Please give statistical data on the number of applications mentioning source and/or country of origin of genetic resources and/or traditional knowledge, following the legal requirement as listed under 1) in your country. If such data are not available, please give an estimate of the number of such applications. No such data is available for the reasons stated. 4) Please indicate whether administrative or judicial decisions on the application of the legal requirement as listed under 1) are available. If yes, please provide the text of such decisions. There are no administrative or judicial decisions on the application of the legal requirement as listed under 1) because there is no legal requirement for mentioning source and/or country of genetic resources and/or traditional knowledge in the US. 5) If there is no legal requirement of indicating the source and/or country of origin of genetic resources and/or traditional knowledge in patent applications for inventions based on such genetic resources or traditional knowledge in your country: Do you know of any project of law in your country dealing with the topic? If yes please provide the corresponding text and 5

review it for the questions a) to i) as under 1). Please include also links to websites which would allow us to follow the progress on these projects of law. No. While the United States has been monitoring the proposals that have been made in a variety of fora to allow or mandate that national patent legislation require the declaration of the source of genetic resources and traditional knowledge in patent applications as well as demands for sharing of benefits from the commercialization of products utilizing them, the US government, with the strong support of US companies, has taken the position that these initiatives are unwise and unnecessary. There are no pending bills or discussions that would suggest that legislation will be introduced on these issues within the United States. It should also be noted that the United States is not a party to the Convention on Biological Diversity, and no pending legislation exists that would alter that status. 6